150 related articles for article (PubMed ID: 31672556)
1. Letter to the editor: Challenges and opportunities in the development of future CFTR modulator options for people with CF.
Downey DG; Taylor-Cousar J
J Cyst Fibros; 2020 Jan; 19(1):e1-e2. PubMed ID: 31672556
[No Abstract] [Full Text] [Related]
2. FDA OKs first in vitro route to expanded approval.
Kingwell K
Nat Rev Drug Discov; 2017 Sep; 16(9):591-592. PubMed ID: 28860581
[No Abstract] [Full Text] [Related]
3. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
4. Disease-modifying drug therapy in cystic fibrosis.
Harman K; Dobra R; Davies JC
Paediatr Respir Rev; 2018 Mar; 26():7-9. PubMed ID: 28583720
[TBL] [Abstract][Full Text] [Related]
5. Drugs during pregnancy and breast feeding in women diagnosed with Cystic Fibrosis - An update.
Kroon MAGM; Akkerman-Nijland AM; Rottier BL; Koppelman GH; Akkerman OW; Touw DJ
J Cyst Fibros; 2018 Jan; 17(1):17-25. PubMed ID: 29233472
[No Abstract] [Full Text] [Related]
6. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
Hoy SM
Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
[TBL] [Abstract][Full Text] [Related]
7. New drug treatments for cystic fibrosis.
Smyth RL
BMJ; 2020 Jan; 368():m118. PubMed ID: 31959620
[No Abstract] [Full Text] [Related]
8. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
10. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
Mayer-Hamblett N; Boyle M; VanDevanter D
Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
[TBL] [Abstract][Full Text] [Related]
11. Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility.
Rubin JL; Kreindler JL
J Cyst Fibros; 2024 Mar; 23(2):368-369. PubMed ID: 38438296
[No Abstract] [Full Text] [Related]
12. Recent Progress in the Discovery and Development of Small-Molecule Modulators of CFTR.
Kym PR; Wang X; Pizzonero M; Van der Plas SE
Prog Med Chem; 2018; 57(1):235-276. PubMed ID: 29680149
[TBL] [Abstract][Full Text] [Related]
13. Challenges in the use of highly effective modulator treatment for cystic fibrosis.
Ramos KJ; Pilewski JM; Taylor-Cousar JL
J Cyst Fibros; 2021 May; 20(3):381-387. PubMed ID: 33531206
[TBL] [Abstract][Full Text] [Related]
14. Corrector combination therapies for F508del-CFTR.
Hanrahan JW; Matthes E; Carlile G; Thomas DY
Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476
[TBL] [Abstract][Full Text] [Related]
15. Important steps in the journey to highly effective CFTR modulator access for people with CF.
VanDevanter DR; Mayer-Hamblett N
J Cyst Fibros; 2019 Sep; 18(5):577-578. PubMed ID: 31500809
[No Abstract] [Full Text] [Related]
16. The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial.
Durmowicz AG; Lim R; Rogers H; Rosebraugh CJ; Chowdhury BA
Ann Am Thorac Soc; 2018 Jan; 15(1):1-2. PubMed ID: 29020455
[TBL] [Abstract][Full Text] [Related]
17. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
Yeh JT; Yu YC; Hwang TC
J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
[TBL] [Abstract][Full Text] [Related]
18. Cystic Fibrosis Papers of the Year 2016.
Doull I
Paediatr Respir Rev; 2018 Mar; 26():10-12. PubMed ID: 28539217
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
20. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
